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Postmenopausal hyperhidrosis is a form of secondary 
hyperhidrosis, and hormone-replacement therapy is a 
commonly used therapeutic option. However, some wo-
men do not benefit from this treatment, and oral anticho-
linergics are a logical alternative for reducing generali-
zed sweating in these patients. Twenty-one patients were 
medicated with 5 or 10 mg of oxybutynin per day. After 
a 3-month follow-up period, efficacy was assessed with 
the Hyperhidrosis Disease Severity Scale (HDSS) and 
the Dermatology Life Quality Index (DLQI) was used to 
assess the improvement in patients’ quality of life. The 
HDSS score was 3.2 ± 0.4 (mean ± SD) before medication 
and 1.9 ± 0.4 after 3 months. The baseline DLQI score of 
8.4 ± 1.0 was reduced to 4.4 ± 0.9. No serious side-effects 
or adverse events resulted from treatment. Oxybuty-
nin was a well-tolerated, effective, and safe method for 
treating postmenopausal sweating. However, long-term 
medication and the limited effects of the treatment were 
disadvantages. Key words: oxubutynin; hyperhidrosis; 
postmenopause.
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Hyperhidrosis is a benign sympathetic disorder that re-
sults in excessive sweating beyond the level needed to 
cool elevated body temperature. It may have a negative 
effect on the patient’s quality of life. Excessive sweating 
disorders can be classified as primary or secondary hyper-
hidrosis according to their aetiology. Primary hyperhidro-
sis is idiopathic and focal, with a genetic predisposition, 
and sweating is often induced as a response to emotional 
stimuli. Secondary hyperhidrosis may be generalized, 
and is frequently associated with diseases or side-effects 
of several drugs that alter the set point of temperature in 
the hypothalamus (1, 2). Postmenopausal hyperhidrosis 
is classified as secondary hyperhidrosis, and generalized 
sweating is not a rare manifestation of vasomotor symp-
toms. According to the Menopause Epidemiology Study 
in the USA, the prevalence of vasomotor symptoms is 
79% in perimenopausal and 65% in postmenopausal 
women. Frequency (severity) of night sweats every night 
was an average of 2.4 (moderate), 3.2 (severe), and 2.7 
(very severe night sweats) in a typical night (3). 
Various treatments, including hormone-replacement 
therapy, have been used with the aim of alleviating 
symptomatic hyperhidrosis. The non-hormonal  therapies 
used include gabapentin, selective serotonin reuptake 
inhibitors, serotonin noradrenaline reuptake inhibitors, 
acupuncture, and herbal medication. 
Anecdotal evidence and a study of a series of patients 
have demonstrated that generalized hyperhidrosis can be 
treated successfully with oral oxybutynin (2, 4–6). Here, 
we evaluated the safety and effectiveness of oxybutynin 
through our prospective analysis of postmenopausal 
patients who were treated successfully with oxybutynin 
for generalized hyperhidrosis. 
PATIENTS AND METHODS
We reviewed 21 consecutive patients (mean age ± standard 
deviation (SD): 54.1 ± 4.5 years) from November 2004 to De-
cember 2008 who were treated at the Hyperhidrosis Clinic of 
the Yonsei University Health System for moderate to severe 
generalized hyperhidrosis after menopause. These patients 
had been experiencing sweating that was not improved by 
conservative treatments such as hormone-replacement therapy 
or other non-hormonal therapeutic options. We focused only on 
patients’ sweating symptoms in order to select women who were 
suitable for treatment. The inclusion criteria were secondary 
and postmenopausal hyperhidrosis with generalized sweating. 
The exclusion criteria were history of possible concurrent 
underlying disease and use of sweat-inducing drugs within the 
previous month. All patients were given complete information 
about the oxybutynin treatment and its possible complications. 
Written informed consent was obtained from each patient. The 
study was audited through the departmental research briefing, 
and all protocols were in accordance with the ethical principles 
defined by the Declaration of Helsinki. 
A subjective diagnosis was made following careful history-
taking and a physical examination. Objective evaluations of 
sweating, such as the Minor’s iodine-starch test, gravimetric 
test, hygrometric test, or colorimetric test, were not performed 
because whole-body sweating or night sweating were clear 
subjective experiences. Blood pressure, routine blood chemistry, 
and hormonal studies were conducted in some patients in or-
der to rule out other causes of hyperhidrosis. To evaluate the 
effective dosage, each patient was instructed to take 5 mg of 
oxybutynin every day in the morning for one week. If 5 mg of 
oxybutynin was insufficient to reduce sweating, an additional 
5 mg was administered in the evenings. Patients were asked to 
telephone or e-mail us if they noticed side-effects. 
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On return visits after the first week, patients were prescribed 
oxybutynin for 3 months unless they refused to continue the treat-
ment. Patients’ subjective observations and experiences were eva-
luated with a questionnaire 3 months later. Efficacy was measured 
by the patients’ assessment of the tolerability of sweating and 
interference effect of sweating on daily activities on the 4-point 
Hyperhidrosis Disease Severity Scale (HDSS) (Table I) (7). The 
HDSS scores were analysed by comparing scores at baseline with 
scores reported 3 months after treatment. The Dermatology life 
Quality Index (DlQI) is a self-reported questionnaire designed 
to measure the impact of skin diseases on patients’ quality of life 
(8). Baseline and follow-up assessments of the total DlQI scores 
were calculated to evaluate the change in the score. 
Statistical analyses were performed using SPSS 13.0 for Win-
dows. The two-sided Wilcoxon signed-rank test for paired samples 
was used to compare the efficacy of oxybutynin. A p-value less than 
0.05 was considered statistically significant for each analysis. 
RESUlTS
Patients first recognized excessive sweating at a mean 
age of 50.6 ± 3.9 years, and had the symptom for a mean 
duration of 3.5 ± 1.8 years. No patients had a previous 
history of primary hyperhidrosis. Sweating was not 
confined to night episodes in any patient. Twelve pa-
tients had a history of hormone-replacement therapy, 
varying from 6 to 18 months, and three patients were 
still undergoing hormone-replacement therapy. Five 
patients had tried non-hormonal therapy. 
The dose of oxybutynin was 5 mg (19 patients) or 
10 mg (2 patients) according to the patient’s need. The 
baseline HDSS score was 3.2 ± 0.4. All patients showed 
at least a 1.0-point improvement in HDSS score from ba-
seline to 3 months (1.9 ± 0.4) after oxybutynin treatment 
(p < 0.01) (Table II). Sweating was reduced within 2 
days after oxybutynin treatment. However, two patients 
still experienced an uncomfortable level of sweating 
from time to time, albeit at a reduced rate. The baseline 
DlQI score was 8.4 ± 1.0, which decreased to 4.4 ± 0.9 
(p < 0.01) 3 months after treatment (Table II). 
No patients reported serious side-effects or adverse 
events during oxybutynin treatment or at follow-up. 
Minor side-effects, such as dry mouth, occurred in three 
patients, and slight urinary difficulties (feeling of mild 
urinary retension) occurred in one patient. However, 
these symptoms were mild and were tolerated without 
any additional treatment. Five of 7 patients with mild to 
moderate symptoms of urinary incontinence reported that 
their urinary incontinence was relieved after treat ment. 
None of the patients showed side-effects such as dry eyes, 
dizziness, diarrhoea, mydriasis, flushing, and rashes. 
Seventeen patients had hot flushes and two patients ex-
perienced palpitations that were not reduced or eliminated 
after oxybutynin administration. We did not observe any 
other postmenopausal symptoms, including sleep distur-
bance, nervousness, depression, vertigo, headache, fati-
gue, arthralgia, and vaginal dryness during the study. 
DISCUSSION
Secondary hyperhidrosis manifesting as generalized 
sweating may be associated with various systemic 
causes, including menopause, and the mechanism of 
the change in sensitivity of the hypothalamic set point 
remains unclear. However, symptoms that are alleviated 
by hormone-replacement therapy suggest that the cause 
is falling levels of oestrogen. Oestrogen ameliorates 
hot flushes by increasing the sweating threshold in the 
thermo-neural zone (9). As a result, hormone-repla-
cement therapy, which was introduced approximately 
70 years ago, was once considered the gold standard 
for the treatment of menopausal symptoms. Nowadays 
the use of hormone-replacement therapy is prescribed 
only after taking into account its risks and benefits 
(10). Consequently, a large number of women choose 
not to receive hormone-replacement therapy, and seek 
alternatives, such as phyto-oestrogens and selective 
Table I. Hyperhidrosis Disease Severity Scale (HDSS)
How would you rate the severity of your sweating? Score
My generalized sweating is never noticeable and never interferes 
with my daily activities.
1
My generalized sweating is tolerable but sometimes interferes with 
my daily activities.
2
My generalized sweating is barely tolerable and frequently 
interferes with my daily activities.
3
My generalized sweating is intolerable and always interferes with 
my daily activities.
4
Table II. Individual and mean ± SD scores (all female) on the 
Hyperhidrosis Disease Severity Scale (HDSS) and Dermatology 




Before After Before After
1 58 4 2 9 5
2 57 3 2 8 4
3 61 3 2 8 5
4 60 3 2 10 4
5 62 4 2 8 3
6 57 3 1 9 4
7 51 3 2 9 4
8a 51 3 2 7 5
9 48 3 2 8 4
10 55 4 2 8 6
11 49 3 2 8 3
12 51 3 2 10 5
13 53 3 1 8 4
14 53 3 2 10 6
15 52 3 2 7 5
16 57 4 2 9 4
17 50 3 2 8 5
18 60 3 1 7 3
19 53 4 2 8 4
20 46 3 2 10 4
21a 52 3 2 7 6
Mean ± SD 54.1 ± 4.5 3.2 ± 0.4 1.9 ± 0.4a 8.4 ± 1.0 4.4 ± 0.9b
aThe patient received the higher dose of 10 mg drug.
bp < 0.01
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oestrogen receptor modulators, in an attempt to relieve 
vasomotor symptoms and sweating. Anticholinergics 
are expected to be more powerful for controlling swea-
ting than conventional therapies. 
Although oral anticholinergics have been used for 
more than two decades, side-effects may limit their use 
in treatment. Propantheline, glycopyrrolate,  oxybutynin, 
and benzotropine may be effective  (11, 12). Glycopyrro-
late and oxybutynin are thought to pose fewer unwanted 
effects than other anti-cholinergics, such as atropine, 
and both have been used in treatment of hyperhidrosis 
(2, 5, 6). They reduce the action of acetylcholine on 
sweat glands, and have a lesser affinity for crossing 
the blood-brain barrier unlike other anticholinergics. 
Therefore, they are less likely to produce side-effects 
(5). Oxybutynin is frequently administered to prevent 
pollakisuria and hyper-reflectory urine bladder because 
of its antispasmodic and anticholinergic effects at a maxi-
mal dose of 20 mg daily. In our study (13) we assessed 
the effectiveness of low doses of oxybutynin during a 
3-month follow-up period in hyperhidrosis patients.  
An objective assessment, such as gravimetric me-
asurement, does not take the patient’s daily activity and 
quality of life into account (14). The patient’s distress due 
to sweating is subjective to personal experience that the 
degree and patterns of sweating may vary considerably 
from moment to moment dependent on factors such as 
the time of day and emotional stimuli (15). In comparison 
with gravimetric measurements, which merely assess the 
quantitative sum of sweating, HDSS measures the effec-
tiveness of therapy via patients’ subjective  assessment of 
their tolerability of sweating. In addition, we also used the 
DlQI as a subjective evaluation of the disability caused by 
sweating. The self-evaluation scale was confirmed as use-
ful in assessing research or clinical protocols to provide the 
necessary validation in wider spectra of patients (16).
In our study, the mean HDSS and DlQI scores before 
oxybutynin treatment were high, indicating that patients 
with moderate to severe postmenopausal hyperhidrosis 
are considerably impaired in their daily activities, and that 
the adverse effects of excessive sweating decreases their 
quality of life. Our assessment of the changes in HDSS 
and DlQI in response to oxybutynin treatment showed 
that oxybutynin treatment resulted in the reduction of 
HDSS and DlQI scores. However, this result was less 
favourable than in another open-label study that was con-
ducted on patients who had diverse causes of idiopathic 
sweating with generalized hyperhidrosis (6). In Tupker’s 
study, baseline DlQI scores were higher (15.9 ± 6.9) than 
those of our patients’ (8.4 ± 1.0). Old age and culturally-
defined acceptance of sweating in our patients seem to be 
a reason. The study of Tupker et al. also showed a greater 
decrease in the score to 3.7 ± 5.2 after treatment and a 
higher incidence of adverse effects with fixed doses (2.5 
mg 3 times daily/5 mg 3 times daily). Although our final 
score of 4.4 ± 0.9 was higher, the incidence of side-effects 
was lower due to a low dose of oxybutynin (5 mg, once 
daily) or a long-term interval of a dosing regimen (5 mg 
in the morning and evening).
Our study supports previous findings that oral admi-
nistration of oxybutynin effectively reduces generalized 
sweating in secondary hyperhidrosis (6). Moreover, no 
patients demonstrated drug intolerance to oral intake of 
oxybutynin during the 3-month follow-up period. The 
need for sustained administration is the main drawback. 
Although our present evaluation has limitations inherent 
to an open-label study, oxybutynin therapy seems to pro-
vide a simple, safe and reasonably effective treatment 
for severe postmenopausal sweating.
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